N/A
Manufactured by Fresenius Kabi USA, LLC
12,161 FDA adverse event reports analyzed
Last updated: 2026-04-15
DACARBAZINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Fresenius Kabi USA, LLC. The most commonly reported adverse reactions for DACARBAZINE include FEBRILE NEUTROPENIA, OFF LABEL USE, NEUTROPENIA, PYREXIA, DRUG INEFFECTIVE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for DACARBAZINE.
Out of 7,108 classified reports for DACARBAZINE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 12,161 FDA FAERS reports that mention DACARBAZINE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include FEBRILE NEUTROPENIA, OFF LABEL USE, NEUTROPENIA, PYREXIA, DRUG INEFFECTIVE, DISEASE PROGRESSION. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Fresenius Kabi USA, LLC in connection with DACARBAZINE. Always verify the specific product and NDC with your pharmacist.